8,655 Studies Reviewed. 86.9% Found Biological Effects. The Evidence is Clear.
Shield Your Body
Whole Body / General

Effects of moderate static magnetic fields on voltage-gated potassium ion channels in sympathetic neuron-like PC12 cells

Bioeffects Seen

Kaneda E, Kawai T, Okamura Y, Miyagawa S · 2025

Share:

Moderate static magnetic field exposure reduces potassium channel function in sympathetic neuron-like cells, potentially decreasing neuronal excitability through altered gene expression.

Plain English Summary

Summary written for general audiences

This study examined how moderate static magnetic fields affect voltage-gated potassium (Kv) channels in PC12 cells, which model sympathetic neurons. The researchers found that 18 hours of magnetic field exposure significantly reduced Kv channel current density, with effects persisting after exposure ended, and identified 37 genes whose expression changed in response to the magnetic field, suggesting activation of pathways that inhibit neuronal excitability.

Why This Matters

Voltage-gated potassium channels are critical regulators of neuronal excitability and action potential repolarization, so changes in their function could have significant physiological consequences. The persistence of effects after magnetic field removal suggests potential lasting cellular modifications rather than purely transient physical effects.

Exposure Information

Specific exposure levels were not quantified in this study.

Cite This Study
Kaneda E, Kawai T, Okamura Y, Miyagawa S (2025). Effects of moderate static magnetic fields on voltage-gated potassium ion channels in sympathetic neuron-like PC12 cells.
Show BibTeX
@article{kaneda_e_kawai_t_okamura_y_miyagawa_s_ce4066,
  author = {Kaneda E and Kawai T and Okamura Y and Miyagawa S},
  title = {Effects of moderate static magnetic fields on voltage-gated potassium ion channels in sympathetic neuron-like PC12 cells},
  year = {2025},
  
  
}
PubMed: 40119575

Quick Questions About This Study

This appears to be a database classification error. The EMPA-KIDNEY trial studied empagliflozin medication for chronic kidney disease patients, with no electromagnetic field exposure component. It should not be included in EMF research collections.
No connection exists between empagliflozin and electromagnetic fields. This sodium-glucose co-transporter 2 inhibitor is a pharmaceutical drug that works through biochemical pathways, not electromagnetic mechanisms. The study examined healthcare costs and quality of life outcomes.
Researchers studied whether empagliflozin (10 mg daily) improved quality-adjusted life years and reduced healthcare costs in 6,609 chronic kidney disease patients over 2-4 years, compared to placebo. No EMF exposure was involved.
While both examine health outcomes, pharmaceutical trials like EMPA-KIDNEY use completely different methodologies than EMF exposure studies. Drug trials focus on biochemical mechanisms, while EMF research investigates electromagnetic field biological interactions through different pathways.
EMF research databases must implement strict classification criteria to separate genuine electromagnetic exposure studies from unrelated medical research. Clear frequency ranges, exposure parameters, and biological endpoints should be required for inclusion to maintain scientific integrity.